Abstract
Aim and Objective: To evaluate a set of seventy phytochemicals for their potential ability to bind the inhibitor of nuclear factor kappaB kinase beta (IKK-β) which is a prime target for cancer and inflammatory diseases.
Materials and Methods: Seventy phytochemicals were screened against IKK-β enzyme using DFT-based molecular docking technique and the top docking hits were carried forward for molecular dynamics (MD) simulation protocols. The ADME-Toxicity analysis was also carried out for the top docking hits.
Results: Sesamin, matairesinol and resveratrol were found to be the top docking hits with a total score of -413 kJ/mol, -398.11 kJ/mol and 266.73 kJ/mol, respectively. Glu100 and Gly102 were found to be the most common interacting residues. The result from MD simulation observed a stable trajectory with a binding free energy of -107.62 kJ/mol for matairesinol, -120.37 kJ/mol for sesamin and -40.56 kJ/mol for resveratrol. The ADME-Toxicity prediction observed that these compounds fall within the permissible area of Boiled-Egg and it does not violate any rule for pharmacological criteria, drug-likeness etc.
Conclusion: The study interprets that dietary phytochemicals are potent inhibitors of IKK-β enzyme with favorable binding affinity and less toxic effects. In fact, there is a gradual rise in the use of plant-derived molecules because of its lesser side effects compared to chemotherapy. The study has also provided an insight by which the phytochemicals inhibited the IKK-β enzyme. The investigation would also provide in understanding the inhibitory mode of certain dietary phytochemicals in treating cancer.
Keywords: IKK-β, MD simulation, docking, cancer, DFT, enzyme.
Graphical Abstract
[http://dx.doi.org/10.1101/cshperspect.a000158] [PMID: 20300203]
[http://dx.doi.org/10.3389/fnmol.2015.00077] [PMID: 26733801]
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0123] [PMID: 18794072]
[http://dx.doi.org/10.1038/nature09853] [PMID: 21423167]
[http://dx.doi.org/10.1016/j.tcb.2009.05.006] [PMID: 19648011]
[http://dx.doi.org/10.1038/nri2423] [PMID: 18927578]
[http://dx.doi.org/10.1146/annurev.immunol.021908.132641] [PMID: 19302050]
[http://dx.doi.org/10.1002/(SICI)1098-2396(200002)35:2<151:AID-SYN8>3.0.CO;2-P] [PMID: 10611641]
[http://dx.doi.org/10.1080/10408398.2015.1129310] [PMID: 26853447]
[http://dx.doi.org/10.1097/MPA.0b013e31821f677d] [PMID: 21697760]
[http://dx.doi.org/10.1155/2014/625792] [PMID: 25243166]
[http://dx.doi.org/10.2174/187152012803833026] [PMID: 22583408]
[http://dx.doi.org/10.1016/j.ctrv.2011.03.001] [PMID: 21481535]
[http://dx.doi.org/10.1021/jm051197e] [PMID: 16722650]
[http://dx.doi.org/10.1021/ja01478a001]
[http://dx.doi.org/10.1021/ja00364a005]
[http://dx.doi.org/10.1016/S0031-8914(34)90011-2]
[http://dx.doi.org/10.1021/ja983494x]
[http://dx.doi.org/10.1111/j.1476-5381.2011.01608.x] [PMID: 21797846]
[http://dx.doi.org/10.3390/cells7090115] [PMID: 30142927]
[http://dx.doi.org/10.1016/j.xphs.2018.07.026] [PMID: 30077700]
[http://dx.doi.org/10.1177/1087057115617456] [PMID: 26597958]